Choose Your Country or Region

Ipilimumab (anti-CTLA-4)

Synonyms: MDX-010, BMS-734016

Catalog No.A2001 Purity:99.83%

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.

Ipilimumab (anti-CTLA-4) Chemical Structure

Click to purchase the isotype control of Ipilimumab (anti-CTLA-4)

Selleck's Ipilimumab (anti-CTLA-4) has been cited by 15 publications

1 Customer Reviews

Purity & Quality Control

Batch: Purity: 99.83% Protein concentration: 5mg/ml Endotoxin Level: ≤1 EU/mg

99.83

Choose Selective Immunology & Inflammation related Inhibitors

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description

Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.

Features

Human IgG1

Targets

CTLA-4 ^[1]
(Cell-free assay)

In Vitro
In vitro	Pembrolizumab plus ipilimumab and nivolumab plus ipilimumab with chemotherapy have been approved by FDA for the first-line treatment of NSCLC patients.^[1]
Cell Research:	For the intracellular cytokine analysis of TILs, cells from dissociated tumors in the density range of 1×10⁵ to 1×10⁶ cells were cultured in a 96-well U-bottom plate containing 10 µg/mL of pembrolizumab, 10 µg/mL of ipilimumab, soluble 50 ng/mL of anti-CD3, and 50 ng/mL of anti-CD28 for 24 h at 37°C, followed by the addition of brefeldin A and monensin. To measure interferon (IFN)-γ and tumor necrosis factor (TNF) secretion levels by CD8⁺ TILs according to PD-1 expression on anti-CD3 and anti-CD28 stimulation, the pre-incubation step without brefeldin A and monensin for 24 h was omitted. After 12 h, the cells were harvested and stained. Intracellular cytokines were stained after surface staining, fixation, and permeabilization with Foxp3 fixation/permeabilization solution.

In Vitro

In vitro

Pembrolizumab plus ipilimumab and nivolumab plus ipilimumab with chemotherapy have been approved by FDA for the first-line treatment of NSCLC patients.^[1]

Cell Research:

For the intracellular cytokine analysis of TILs, cells from dissociated tumors in the density range of 1×10⁵ to 1×10⁶ cells were cultured in a 96-well U-bottom plate containing 10 µg/mL of pembrolizumab, 10 µg/mL of ipilimumab, soluble 50 ng/mL of anti-CD3, and 50 ng/mL of anti-CD28 for 24 h at 37°C, followed by the addition of brefeldin A and monensin. To measure interferon (IFN)-γ and tumor necrosis factor (TNF) secretion levels by CD8⁺ TILs according to PD-1 expression on anti-CD3 and anti-CD28 stimulation, the pre-incubation step without brefeldin A and monensin for 24 h was omitted. After 12 h, the cells were harvested and stained. Intracellular cytokines were stained after surface staining, fixation, and permeabilization with Foxp3 fixation/permeabilization solution.

In Vivo
In vivo	⁶⁴Cu-labeled ipilimumab may be used to noninvasively monitor CTLA-4-expressing tissues in vivo.^[2]
Animal Research	AnimalModels:Female athymic nude mice of human lung adenocarcinoma xenograft model Formulation:buffer-exchanged to PBS, and conjugated with DOTA for radiolabeling with ⁶⁴Cu (t1/2 = 12.7 h) Dosages:~1 mg/mL Administration:i.v.^[2]

In Vivo

In vivo

⁶⁴Cu-labeled ipilimumab may be used to noninvasively monitor CTLA-4-expressing tissues in vivo.^[2]

Animal Research

AnimalModels:Female athymic nude mice of human lung adenocarcinoma xenograft model
Formulation:buffer-exchanged to PBS, and conjugated with DOTA for radiolabeling with ⁶⁴Cu (t1/2 = 12.7 h)
Dosages:~1 mg/mL
Administration:i.v.^[2]

References
[1] Kim CG, et al. J Immunother Cancer. 2021 Dec;9(12):e002780. [2] Ehlerding EB, et al. Mol Pharm. 2017 May 1;14(5):1782-1789.

References

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	477202-00-9
Isotype	Human IgG1
Source	CHO cells
Formulation	PBS buffer, pH 7.2
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.